RYOIX: Rydex Biotechnology Inv

Welcome to MutualFunds.com

Please help us personalize your experience and select the one that best describes you.

Your personalized experience is almost ready.

Join other Individual Investors receiving FREE personalized market updates and research. Join other Institutional Investors receiving FREE personalized market updates and research. Join other Financial Advisors receiving FREE personalized market updates and research.

Thank you!

Check your email and confirm your subscription to complete your personalized experience.

Thank you for your submission

We hope you enjoy your experience

Channels

Fixed income news, reports, video and more.

Municipal bonds news, reports, video and more.

Practice management news, reports, video and more.

Portfolio management news, reports, video and more.

Retirement news, reports, video and more.

Learn from industry thought leaders and expert market participants.

Find the latest content and information here about the 2019 Charles Schwab Impact Conference.

Advisors

Receive email updates about fund flows, news, upcoming CE accredited webcasts from industry thought leaders and more.

Content focused on helping financial advisors build successful client relationships and grow their business.

Content geared towards helping financial advisors build better client portfolios.

Get insights on the industry trends and investment news from leading fund managers and experts.

RYOIX Rydex Biotechnology Inv


Profile

RYOIX - Profile

Vitals

  • YTD Return 12.0%
  • 3 Yr Annualized Return 2.4%
  • 5 Yr Annualized Return -1.8%
  • Net Assets $240 M
  • Holdings in Top 10 45.6%

52 WEEK LOW AND HIGH

$94.09
$63.72
$94.95

Expenses

OPERATING RELATED FEES

  • Expense Ratio 1.48%

SALES FEES

  • Front Load N/A
  • Deferred Load N/A

BROKERAGE FEES

  • Turnover 64.00%

TRADING FEES

  • Max Redemption Fee N/A

Min Investment

  • Standard (Taxable) $2,500
  • IRA $1,000

Fund Classification


Distributions

  • YTD Total Return 12.0%
  • 3 Yr Annualized Total Return 2.4%
  • 5 Yr Annualized Total Return -1.8%
  • Capital Gain Distribution Frequency Annually
  • Net Income Ratio -0.56%
DIVIDENDS
  • Dividend Yield 0.0%
  • Dividend Distribution Frequency Annually

Fund Details

  • Legal Name
    Rydex Biotechnology Fund
  • Fund Family Name
    Rydex Funds
  • Inception Date
    Apr 01, 1998
  • Shares Outstanding
    N/A
  • Share Class
    Inv
  • Currency
    USD
  • Domiciled Country
    United States
  • Manager
    Michael Byrum

Fund Description

Under normal circumstances, the fund invests substantially all (at least 80%) of its net assets in equity securities of Biotechnology Companies that are traded in the United States and in derivatives, which primarily consist of futures contracts and options on securities, futures contracts, and stock indices. It may invest to a significant extent in the securities of Biotechnology Companies that have small to mid-sized capitalizations. The fund is non-diversified.


Sign up for Advisor Access

Receive email updates about best performers, news, CE accredited webcasts and more.


Categories

Performance

RYOIX - Performance

Return Ranking - Trailing

Period RYOIX Return Category Return Low Category Return High Rank in Category (%)
YTD 12.0% -9.8% 16.6% 16.15%
1 Yr 21.4% -13.1% 26.5% 11.86%
3 Yr 2.4%* -14.4% 22.1% 66.67%
5 Yr -1.8%* -12.1% 10.5% 50.00%
10 Yr 14.8%* -1.6% 17.8% 5.95%

* Annualized

Return Ranking - Calendar

Period RYOIX Return Category Return Low Category Return High Rank in Category (%)
2019 19.9% 5.7% 55.4% 52.14%
2018 -19.7% -25.3% 21.5% 95.50%
2017 23.0% -10.8% 43.9% 22.94%
2016 -19.5% -31.6% 6.9% 67.92%
2015 7.2% -20.4% 13.8% 4.95%

Total Return Ranking - Trailing

Period RYOIX Return Category Return Low Category Return High Rank in Category (%)
YTD 12.0% -9.8% 16.6% 16.15%
1 Yr 21.4% -13.1% 26.5% 11.86%
3 Yr 2.4%* -14.4% 25.2% 72.97%
5 Yr -1.8%* -12.1% 15.2% 69.23%
10 Yr 14.8%* -1.6% 19.5% 32.14%

* Annualized

Total Return Ranking - Calendar

Period RYOIX Return Category Return Low Category Return High Rank in Category (%)
2019 19.9% 5.7% 55.4% 52.14%
2018 -19.7% -25.3% 22.2% 95.50%
2017 23.0% -10.8% 45.8% 27.52%
2016 -19.5% -26.4% 8.7% 80.19%
2015 7.2% -16.6% 15.2% 38.61%

NAV & Total Return History


Holdings

RYOIX - Holdings

Concentration Analysis

RYOIX Category Low Category High RYOIX % Rank
Net Assets 240 M 2.35 M 47.5 B 70.15%
Number of Holdings 54 27 433 86.57%
Net Assets in Top 10 132 M 579 K 16.9 B 64.18%
Weighting of Top 10 45.56% 21.5% 76.0% 29.85%

Top 10 Holdings

  1. AbbVie Inc 6.75%
  2. Amgen Inc 6.32%
  3. Gilead Sciences Inc 5.46%
  4. Vertex Pharmaceuticals Inc 4.88%
  5. Regeneron Pharmaceuticals Inc 4.59%
  6. Illumina Inc 4.29%
  7. Biogen Inc 4.25%
  8. Moderna Inc 3.03%
  9. Alexion Pharmaceuticals Inc 3.01%
  10. Seattle Genetics Inc 2.99%

Asset Allocation

Weighting Return Low Return High RYOIX % Rank
Stocks
99.53% 65.31% 100.26% 23.88%
Cash
1.97% -0.23% 34.69% 44.03%
Preferred Stocks
0.00% 0.00% 4.57% 99.25%
Convertible Bonds
0.00% 0.00% 0.00% 99.25%
Bonds
0.00% 0.00% 16.54% 99.25%
Other
-1.50% -1.50% 9.19% 99.25%

Stock Sector Breakdown

Weighting Return Low Return High RYOIX % Rank
Healthcare
97.47% 60.00% 100.00% 93.28%
Basic Materials
2.53% 0.00% 2.53% 2.24%
Utilities
0.00% 0.00% 0.00% 99.25%
Technology
0.00% 0.00% 15.32% 99.25%
Real Estate
0.00% 0.00% 5.63% 99.25%
Industrials
0.00% 0.00% 3.92% 99.25%
Financial Services
0.00% 0.00% 1.53% 99.25%
Energy
0.00% 0.00% 0.33% 99.25%
Communication Services
0.00% 0.00% 5.13% 99.25%
Consumer Defense
0.00% 0.00% 36.48% 99.25%
Consumer Cyclical
0.00% 0.00% 0.96% 99.25%

Stock Geographic Breakdown

Weighting Return Low Return High RYOIX % Rank
US
95.48% 52.09% 99.18% 5.97%
Non US
4.05% 0.00% 44.37% 96.27%

Expenses

RYOIX - Expenses

Operational Fees

RYOIX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Expense Ratio 1.48% 0.10% 25.14% 44.62%
Management Fee 0.85% 0.00% 1.30% 72.39%
12b-1 Fee N/A 0.00% 1.00% N/A
Administrative Fee 0.25% 0.03% 0.40% 92.86%

Sales Fees

RYOIX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Front Load N/A 3.50% 5.75% N/A
Deferred Load N/A 1.00% 5.00% N/A

Trading Fees

RYOIX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Max Redemption Fee N/A 1.00% 2.00% N/A

Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

RYOIX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Turnover 64.00% 0.70% 248.00% 82.31%

Distributions

RYOIX - Distributions

Dividend Yield Analysis

RYOIX Category Low Category High RYOIX % Rank
Dividend Yield 0.00% 0.00% 0.06% 99.25%

Dividend Distribution Analysis

RYOIX Category Low Category High Category Mod
Dividend Distribution Frequency Annually Annually Annually Annually

Net Income Ratio Analysis

RYOIX Category Low Category High RYOIX % Rank
Net Income Ratio -0.56% -2.53% 2.12% 77.69%

Capital Gain Distribution Analysis

RYOIX Category Low Category High Capital Mode
Capital Gain Distribution Frequency Annually Annually Annually Annually

Dividend Payout History

View More +

Fund Manager Analysis

RYOIX - Fund Manager Analysis

Managers

Michael Byrum


Start Date

Tenure

Tenure Rank

Apr 01, 1998

22.26

22.3%

Michael P. Byrum, CFA, Senior Vice President—Mr. Byrum has been associated with the Security Investors since 1993. Mr. Byrum was the inaugural portfolio manager for many of the Rydex products, including the Rydex leveraged and inverse funds, sector fund lineup and alternative investment portfolios. Today, Mr. Byrum continues to play an instrumental role in product development and investment strategy at Guggenheim Investments and oversees the trading, research and portfolio management activities of the quantitative strategies team, which focuses on target beta, alternative and asset allocation strategies. He is the chairman of the Investment Strategy Committee and is a member of the Risk Management Committee and Credit Review Committee. Prior to joining the Security Investors, Mr. Byrum served in a brokerage capacity with Money Management Associates, the registered investment advisor to Rushmore Funds, Inc. He earned a B.S. in finance from the Miami University of Ohio. He also has earned the right to use the Chartered Financial Analyst® designation and is a member of the CFA Institute and the CFA Society of Washington.

Ryan Harder


Start Date

Tenure

Tenure Rank

Mar 14, 2008

12.3

12.3%

Ryan A. Harder, CFA, Portfolio Manager of Security Investors. Mr. Harder joined the Investment Manager in 2010.He also joined Rydex Investments in 2004 as an assistant portfolio manager, was promoted to portfolio manager in 2005 and has served in his current capacity since 2008. Prior to joining Rydex Investments, he served in various capacities with WestLB Asset Management, including as an assistant portfolio manager, and worked in risk management at CIBC World Markets.He holds a B.A. in Economics from Brock University in Ontario, Canada and a Master of Science in International Securities, Investment and Banking from the ICMA Centre at the University of Reading in the U.K. Harder holds the Chartered Financial Analyst designation.

Tenure Analysis

Category Low Category High Category Average Category Mode
0.08 22.81 8.53 20.18